At a glance
Type
GLP-1 + glucagon dual agonist
Molecular weight
≈4563.1 g/mol
Studied for
Weight managementBlood-sugar controlLiver fatEnergy expenditure
Mazdutide (IBI362) is a GLP-1 and glucagon receptor dual agonist — an oxyntomodulin-based peptide developed by Innovent and Eli Lilly. Like tirzepatide’s dual approach, it hits two receptors, but its second target is glucagon rather than GIP.
How mazdutide works
Mazdutide is built on the oxyntomodulin scaffold and activates two receptors at once. The GLP-1 arm suppresses appetite and improves glucose control; the glucagon arm adds increased energy expenditure and helps mobilise liver fat. Combining both is the mechanism behind the weight-loss and cardiometabolic effects seen in its trials.
What the research shows
- Obesity, Phase 2 (Ji et al., Nat Commun 2023). A 24-week trial in Chinese adults showed dose-dependent, clinically meaningful weight loss versus placebo.
- Higher-dose Phase 1b (Zhang et al., 2022). Confirmed weight loss and tolerability at 9–10 mg doses.
- Phase 3 — GLORY-1 (NEJM 2025). The first Phase 3 (~610 participants) met its primary and key secondary endpoints, with significant weight loss, reduced liver fat and improved cardiometabolic markers over 48 weeks.
Candour: mazdutide is investigational — its trials have been conducted largely in Chinese populations, and while it received an initial approval in China (2025), it is not a marketed medicine in most markets. Long-term, broad-population data are still accumulating. Use belongs under a physician’s guidance.
Molecular specification
| Type | GLP-1 + glucagon dual agonist (oxyntomodulin analog) |
| Sequence | 33-aa peptide with C20 fatty-diacid |
| Molecular formula | C210H322N46O67 |
| Molecular weight | ≈4563.1 g/mol |
| CAS number | 2259884-03-0 |
| Status | Investigational |
Quality and sourcing
Every batch of Azzurri Wellness mazdutide is compounded through a Registered 503B outsourcing facility under GMP-compliant processes, HPLC-tested for purity and potency, and third-party lab verified. Shipped cold-pack when needed to protect stability.
References
- Ji L, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023;14:8289. Nature
- Zhang Y, et al. Safety and efficacy of mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a phase 1b trial. eClinicalMedicine. 2022. PMC
Compiled by the Azzurri Wellness Research Team and checked against the cited literature. Educational only — not medical advice.
